By Maureen Martino oche and partner Plexxikon have reported a rare success in the challenging field of melanoma. Closely-watched drug PLX4032 extended the lives of subjects with metastatic melanoma in a Phase III trial. Additionally, patients receiving PLX4032 lived longer without their disease getting progressing compared to those who received the current standard of care. The …
By George Miller Data, data everywhere, but not an insight to be gleaned. That’s the growing problem of drug discovery and development, according to speakers at a recent Financial Times pharma and biotech conference. Roche finds that despite its data volume doubling in 15 months, it gains little in the way ofdevelopment insight. The company struggles to filter and make sense of the …
By John Carroll What’s Roche willing to bet hundreds of millions of dollars on next year? This morning the pharma giant answered that question by highlighting its 14 late-stage prospects in the pipeline, promising that it has the potential to file for regulatory approval on 10 new molecular entities through 2013. Four of the programs–T-DM1, …
By John Carroll Roche’s pipeline review could set the stage for some new biotech companies to take shape.Bloomberg reports that the Swiss pharma giant intends to slim down its pipeline in the coming weeks and venture groups are keenly interested in seeing if some of the most promising programs and scientific talent could be packaged …
By John Carroll Determined to push ahead on two of the toughest CNS targets in drug development, Roche announced this morning that it is teaming up on two preclinical candidates at reMYND, a Belgian biotech that could earn more than $637 million in milestones if the partners can make their way to the marketplace. ReMYND’s …
By John Carroll Aileron Therapeutics’ stapled peptide platform has won over Roche, which is paying $25 million upfront and up to $1.1 billion more in milestones to explore the potential to deliver a new generation of drugs right to their target. For Aileron, a 2009 Fierce 15 company, the billion-dollar deal represents a key endorsement from …
By John Carroll An experimental personalized cancer therapy from Roche and Plexxikon registered striking results in a recent clinical study, shrinking the tumors in a majority of metastatic melanoma patients who share a common genetic mutation. And a group of experts in the field are lauding the results, saying that the success of this study could …
By John Carroll Belgium’s Galapagos has agreed to expand its R&D collaboration with Roche on new COPD drugs, gaining an extra €150 million in milestones as it broadens its hunt for new drugs to treat smoker’s lung. Roche is adding the new set of milestones on top of the €400 million it originally committed to back …
By Tracey Staton Analysts were cheering Roche today as the Swiss drugmaker posted a 6 percent rise in first-quarter revenues, beating estimates. The company also confirmed its forecasts for the year, with CEO Severin Schwan saying that his company is “fully on track for 2010.” First-quarter sales came in at $11.64 billion. In a way, …
By Maureen Martino Roche intends to keep up its licensing pace even after its massive buyout of Genentech last year, which included gaining access to 16 Phase I or II programs the big Biotech had in its pipeline. Dan Zabrowski, head of partnering at the Swiss company, tells Bloomberg that Roche inked 65 deals last year and plans on pursuing …
